Tazverik
Drug
Epizyme, Inc.
Total Payments
$24.1M
Transactions
6,323
Doctors
1,471
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12.8M | 2,985 | 283 |
| 2023 | $11.3M | 3,338 | 1,270 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.2M | 3,941 | 96.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $670,307 | 204 | 2.8% |
| Food and Beverage | $71,055 | 1,976 | 0.3% |
| Travel and Lodging | $64,905 | 149 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $41,432 | 11 | 0.2% |
| Honoraria | $23,305 | 19 | 0.1% |
| Consulting Fee | $21,973 | 7 | 0.1% |
| Education | $1,078 | 16 | 0.0% |
Payments by Type
Research
$23.2M
3,941 transactions
General
$894,054
2,382 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | Epizyme, Inc. | $8.8M | 1 |
| A Phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC) | Epizyme, Inc. | $1.5M | 0 |
| A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC) | Epizyme, Inc. | $1.1M | 0 |
| A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463 | Epizyme, Inc. | $1.0M | 0 |
| A Phase II trial of tazemetostat plus mosunetuzumab in untreated follicular lymphoma | Ipsen Biopharmaceuticals, Inc | $999,050 | 0 |
| A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Epizyme, Inc. | $986,018 | 0 |
| CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | Epizyme, Inc. | $929,500 | 0 |
| A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | Ipsen Biopharmaceuticals, Inc | $885,477 | 0 |
| A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | Epizyme, Inc. | $739,685 | 0 |
| A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | Epizyme, Inc. | $633,500 | 0 |
| A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | Ipsen Biopharmaceuticals, Inc | $568,904 | 0 |
| A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463 | Ipsen Biopharmaceuticals, Inc | $557,718 | 0 |
| A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | Epizyme, Inc. | $468,754 | 0 |
| A feasibility trial of tazemetostat plus CAR T cell therapy in B-cell lymphomas | Ipsen Biopharmaceuticals, Inc | $452,400 | 0 |
| A feasibility trial of tazemetostat plus CAR T cell therapy in B-cell lymphomas | Epizyme, Inc. | $395,850 | 0 |
| A Phase II trial of tazemetostat plus mosunetuzumab in untreated follicular lymphoma | Epizyme, Inc. | $377,000 | 0 |
| Phase I trial of tazemetostat in combination with venetoclax in patients with non-Hodgkin lymphoma | Epizyme, Inc. | $226,200 | 0 |
| Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | Epizyme, Inc. | $210,749 | 0 |
| A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies | Epizyme, Inc. | $202,109 | 0 |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | Ipsen Biopharmaceuticals, Inc | $188,500 | 0 |
Top Doctors Receiving Payments for Tazverik
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $23.2M | 3,951 |
| , M.D | Hematology & Oncology | Pascagoula, MS | $87,303 | 54 |
| , M.D | Hematology | Orlando, FL | $57,848 | 34 |
| , MD | Medical Oncology | Dallas, TX | $40,397 | 16 |
| , M.D | Hematology & Oncology | Murray, UT | $37,453 | 25 |
| , MD | Medical Oncology | Bolivar, MO | $32,958 | 16 |
| , M.D | Hematology & Oncology | Cary, NC | $32,411 | 17 |
| , D.O | Internal Medicine | Omaha, NE | $23,402 | 6 |
| , M.D | Internal Medicine | Omaha, NE | $22,743 | 11 |
| , MD | Hematology & Oncology | Orlando, FL | $20,711 | 11 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $19,860 | 10 |
| , MD | Hematology & Oncology | Fort Worth, TX | $19,740 | 11 |
| , MD | Internal Medicine | Buffalo, NY | $19,204 | 8 |
| , P.A | Medical | Chicago, IL | $17,882 | 26 |
| , M.D. , M.P.H | Hematology & Oncology | Albany, NY | $11,938 | 5 |
| , M.D | Medical Oncology | Bethesda, MD | $11,858 | 6 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $9,918 | 9 |
| , MD | Internal Medicine | Houston, TX | $8,938 | 7 |
| , M.D | Internal Medicine | Waycross, GA | $8,633 | 7 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $8,400 | 1 |
| , M.D | Hematology | Chicago, IL | $8,372 | 3 |
| , MD | Medical Oncology | Philadelphia, PA | $6,904 | 4 |
| , M.D | Hematology & Oncology | Dallas, TX | $6,555 | 2 |
| , M.D | Hematology & Oncology | New York, NY | $6,548 | 2 |
| , M.D., PH. D | Medical Oncology | Miami, FL | $6,539 | 5 |
Ad
Manufacturing Companies
- Epizyme, Inc. $18.8M
- Ipsen Biopharmaceuticals, Inc $5.2M
- Ipsen Bioscience Inc. $2,600
Product Information
- Type Drug
- Total Payments $24.1M
- Total Doctors 1,471
- Transactions 6,323
About Tazverik
Tazverik is a drug associated with $24.1M in payments to 1,471 healthcare providers, recorded across 6,323 transactions in the CMS Open Payments database. The primary manufacturer is Epizyme, Inc..
Payment data is available from 2023 to 2024. In 2024, $12.8M was paid across 2,985 transactions to 283 doctors.
The most common payment nature for Tazverik is "Unspecified" ($23.2M, 96.3% of total).
Tazverik is associated with 20 research studies, including "Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma" ($8.8M).